Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 12/20 | 0.58 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29473672 | 0.84 | OPRL1 (0.55) | OPRL1BACE1F2 | |
| SCHEMBL16407974 | 0.83 | TLR2 (0.43) | TLR2OPRL1BACE1F2 | |
| SCHEMBL15201624 | 0.83 | OPRL1 (0.47) | OPRL1BACE1F2 | |
| SCHEMBL31026565 | 0.82 | OPRL1 (0.52) | OPRL1F2 | |
| SCHEMBL29649210 | 0.81 | TFPI (0.56) | BACE1 | |
| SCHEMBL30974224 | 0.80 | OPRL1 (0.56) | OPRL1BACE1F2 | |
| SCHEMBL30974440 | 0.80 | OPRL1 (0.56) | OPRL1F2 | |
| SCHEMBL9276639 | 0.79 | TLR2 (0.65) | TLR2 | |
| SCHEMBL9273194 | 0.79 | TLR2 (0.65) | TLR2 | |
| SCHEMBL8650135 | 0.79 | TLR2 (0.65) | TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041764-A1 | EXTRACELLULAR VESICLES FOR VACCINE DELIVERY | LONZA SALES AG (CH) | 2026-02-12 | — | — | US | claimed |
| US-20250345412-A1 | Coronavirus Vaccine | The Univesity of Melbourne Grattan Street (AU) | 2025-11-13 | — | — | US | claimed |
| WO-2025235998-A1 | PLURIPOTENT STEM CELL DERIVED MESENCHYMAL STEM CELLS WITH ENHANCED IMMUNE MODULATORY ACTIVITY | IMMORTA BIO, INC. (US) | 2025-11-13 | — | — | WO | claimed |
| US-20250312440-A1 | CHEMICAL SCREEN OF MODULATORS FOR VACCINE ADJUVANTS | THE UNIVERSITY OF CHICAGO (US) | 2025-10-09 | — | — | US | claimed |
| US-20250213684-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | NOVARTIS AG (CH) | 2025-07-03 | — | — | US | claimed |
| EP-4531910-A2 | CHEMICAL SCREEN OF MODULATORS FOR VACCINE ADJUVANTS | The University of Chicago (US) | 2025-04-09 | — | — | EP | claimed |
| US-12239714-B2 | Phosphatidylserine-binding conjugates | CANBAS CO., LTD. (JP) | 2025-03-04 | — | — | US | claimed |
| EP-4456923-A1 | CONJUGATES BINDING PHOSPHATIDYLSERINE AND TOLL-LIKE RECEPTORS | CanBas Co., Ltd. (JP) | 2024-11-06 | — | — | EP | claimed |
| WO-2024186031-A1 | COMPOSITION COMPRISING MAST CELL-CONDITIONED MEDIUM FOR WOUND HEALING | 이화여자대학교 산학협력단 | 2024-09-12 | — | — | WO | claimed |
| CN-118574643-A | Conjugates that bind phosphatidylserine and Toll-like receptors | 三井有限公司 | 2024-08-30 | — | — | CN | claimed |
| EP-4031167-A1 | TREATMENT OF DISC DEGENERATIVE DISEASE AND STIMULATION OF PROTEOGLYCAN SYNTHESIS BY FIBROBLAST CONDITIONED MEDIA AND FORMULATIONS THEREOF | Figene, LLC (US) | 2022-07-27 | — | — | EP | claimed |
| WO-2022133547-A1 | CORONAVIRUS VACCINE | THE UNIVERSITY OF MELBOURNE (AU) | 2022-06-30 | — | — | WO | claimed |
| WO-2022112558-A1 | APPLICATION OF STEM-CELL DERIVED MONOCYTES IN A MONOCYTE ACTIVATION TEST (MAT) FOR THE ASSESSMENT OF PYROGENICITY AND INFLAMMATORY POTENTIAL | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2022-06-02 | — | — | WO | claimed |
| EP-4006546-A1 | APPLICATION OF STEM-CELL DERIVED MONOCYTES IN A MONOCYTE ACTIVATION TEST (MAT) FOR THE ASSESSMENT OF PYROGENICITY AND INFLAMMATORY POTENTIAL | Medizinische Hochschule Hannover (DE) | 2022-06-01 | — | — | EP | claimed |
| EP-3994158-A1 | EXTRACELLULAR VESICLES TARGETING T CELLS AND USES THEREOF | Codiak BioSciences, Inc. (US) | 2022-05-11 | — | — | EP | claimed |
| US-20220133889-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | CHILDREN'S MEDICAL CENTER CORPORATION | 2022-05-05 | — | — | US | claimed |
| CN-114272371-A | Combination therapy comprising anti-PD-1 antibody molecules | 诺华股份有限公司 | 2022-04-05 | — | — | CN | claimed |
| WO-2022066883-A1 | EXTRACELLULAR VESICLES COMPRISING KRAS ANTIGENS AND USES THEREOF | CODIAK BIOSCIENCES, INC. (US) | 2022-03-31 | — | — | WO | claimed |
| CN-114080232-A | Extracellular vesicles for vaccine delivery | 科迪亚克生物科学公司 | 2022-02-22 | — | — | CN | claimed |
| EP-3941937-A2 | EXTRACELLULAR VESICLES FOR VACCINE DELIVERY | Codiak BioSciences, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041764-A1 | EXTRACELLULAR VESICLES FOR VACCINE DELIVERY | EXOSC10, EXOSC5, HLA-DRB1 | TLR2 72/4885OPRL1 4027/4885BACE1 2419/4885 |
| US-20220133889-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | HAVCR2, LGALS3BP, CD274 | TLR2 680/4885OPRL1 4493/4885BACE1 538/4885 |
| US-20250213684-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | HAVCR2, LGALS3BP, CD274 | TLR2 680/4885OPRL1 4493/4885BACE1 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.